These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7530496)

  • 1. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.
    Schmidt-Wolf IG; Huhn D; Neubauer A; Wittig B
    Hum Gene Ther; 1994 Sep; 5(9):1161-8. PubMed ID: 7530496
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.
    Wittig B; Märten A; Dorbic T; Weineck S; Min H; Niemitz S; Trojaneck B; Flieger D; Kruopis S; Albers A; Löffel J; Neubauer A; Albers P; Müller S; Sauerbruch T; Bieber T; Huhn D; Schmidt-Wolf IG
    Hum Gene Ther; 2001 Feb; 12(3):267-78. PubMed ID: 11177563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma.
    Kondo M; Nonomura N; Miki T; Kojima Y; Yokoyama M; Nakano E; Okuyama A
    Oncology; 1998; 55(6):588-93. PubMed ID: 9778628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
    Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 7. Adoptive cellular therapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1991; 12():213-30. PubMed ID: 1931444
    [No Abstract]   [Full Text] [Related]  

  • 8. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T; Yamaguchi Y
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ; Lawson DH; York RM; Graham SD; Murray DR; Gillespie TM; Levitt D; Sell KM
    Arch Surg; 1991 Jul; 126(7):898-903. PubMed ID: 1854252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
    N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.
    Walther MM; Alexander RB; Weiss GH; Venzon D; Berman A; Pass HI; Linehan WM; Rosenberg SA
    Urology; 1993 Sep; 42(3):250-7; discussion 257-8. PubMed ID: 8379024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
    Fleischmann JD; Kim B
    J Urol; 1991 May; 145(5):938-41. PubMed ID: 2016805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.
    Hum Gene Ther; 1992 Dec; 3(6):691-703. PubMed ID: 1482709
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.